Management at South African pharmaceutical multinational Aspen Pharmacare appeared confident when announcing their full year results for 2023, celebrating a record H2 following a shaky start to the year, even as the market expressed reservations about the firm’s performance going into FY2024.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?